Caris Life Sciences (NASDAQ:CAI) executives outlined the company’s growth strategy, product pipeline and financial position during a presentation and Q&A session at a Goldman Sachs event hosted by life science tools and diagnostics analyst Evie Koslosky.
Brian Brille, vice chairman of Caris Life Sciences, said the company sees more opportunity in precision oncology than at any point since its founding in 2008. He said the market is shifting toward molecular medicine at both the cancer center and individual oncologist levels, creating demand for broad testing platforms, large datasets and institutional partnerships.
Company Highlights FDA-Approved Testing Platform
Brille and Milan Radovich, Caris’ chief scientific officer, emphasized the company’s whole exome and whole transcriptome testing platform. Brille said Caris is the only company with an FDA-approved whole exome and whole transcriptome technology, which he said has helped with partnerships, research and reimbursement.
Radovich said Caris has standardized on sequencing “every single gene in the genome and the transcriptome” since 2019, with the goal of identifying drugs or clinical trials for patients with late-stage disease while also building a dataset for research and product development.
Radovich also discussed Caris’ liquid biopsy assay, Caris Assure, which analyzes tumor-derived DNA and RNA in plasma and also sequences the white blood cell layer to help distinguish tumor mutations from clonal hematopoiesis-related mutations. He said this distinction is important because mutations originating from white blood cells could otherwise lead physicians toward inappropriate treatment decisions.
New Products Include ChromoSeq, MyClarity and Detect
Executives highlighted several recently launched or developing products. Radovich said Caris recently launched Caris ChromoSeq, a whole genome test for hematological malignancies initially focused on AML, MDS and MPN. He said the test has a seven-day turnaround time and is intended to replace multiple smaller tests used in hematological cancer evaluation.
Radovich also said Caris launched MyClarity, an AI-based digital pathology test for breast cancer recurrence risk. He described it as a potential replacement for Oncotype, saying it is designed to assess early recurrence risk and better differentiate late recurrence risk five to 15 years after diagnosis. The test uses AI on H&E images and can turn around in about a day, according to Radovich.
Caris Detect, the company’s multi-cancer early detection test, remains a key pipeline focus. Radovich said the test uses high-depth whole genome sequencing and reported previously disclosed case-control data from the Achieve 1 study, which included 3,000 individuals. He said the study showed Stage 1-2 sensitivity of 60.3% and specificity of 99.2%.
Luke Power, Caris’ chief financial officer, said the company has publicly announced an initial launch of Caris Detect through Everlywell’s online platform. He said Caris is finalizing the customer experience and follow-up process before launch, with a goal previously communicated for the first half of the year. Power said Caris plans to rely on partnerships rather than building a large primary care sales force for the product.
Financial Performance and Commercial Investments
Power said Caris reported 79% revenue growth in the first quarter, driven primarily by its molecular profiling business. He said the company has benefited from reimbursement catching up to its technology investments, including its whole exome and whole transcriptome tissue assay.
Power said Caris has gross margins in the 65% range while also generating positive adjusted EBITDA and positive free cash flow. He said the company has produced positive free cash flow in each of the four quarters since its IPO and plans to reinvest that cash flow into the business this year.
Those investments include expanding the commercial organization. Brille said Caris has about 270 field-based team members and is adding people under a new chief commercial officer. Power said the company’s goal is to reach 300 salespeople by the end of the second quarter, expand territories from 146 to 175 and continue investing in electronic health record integrations. He said about 70% of orders currently come in electronically.
Power also said Caris’ FDA-approved MyCancerSEQ tissue assay is priced at $8,455 on the clinical lab fee schedule, while Caris Assure is priced at $3,649. He said the company is pursuing New York State approval and FDA approval for Caris Assure, with the potential to later pursue an ADLT path for improved pricing.
Share Repurchase Signals Confidence
During the Q&A session, Koslosky asked about a share repurchase announced that morning. Brille said the decision reflected the company’s profitability and ability to continue investing in its product pipeline and commercial channel.
“I think it’s also a reflection of our CEO and founder’s confidence about this market and the company overall,” Brille said.
Asked what he believes is underappreciated about Caris, Power pointed to the company’s profitability and technology. He said no other company is performing whole exome and whole transcriptome testing at Caris’ scale, while Caris is also expanding into whole genome testing through Caris Detect.
About Caris Life Sciences (NASDAQ:CAI)
Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.
Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.
